• Pharma Equity Group posted a DKK 2.7 million loss for H1 2026, narrowing from a DKK 17.6 million loss a year earlier.
• Equity rose to DKK 25.8 million as of June 30, while cash and cash equivalents fell to DKK 29,000.
• Total assets climbed to DKK 44.16 million; the Portinho S.A. receivable increased to DKK 39.33 million after an arbitral award confirmed a valid claim.
• Convertible instruments stood at DKK 21.16 million; subordinated convertible loans were DKK 4.42 million.
• Guidance maintained for 2026: revenue of DKK 3.0-8.6 million, negative EBIT of DKK 5.8-11.4 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Equity Group A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140349OMX_____CNEWS_EN_GNW1001257593_en) on August 14, 2026, and is solely responsible for the information contained therein.